Arrowhead Research Corporation(ARWR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ARWR Arrowhead Research Corporation

盘前交易 12-15 08:02:54 EST

70.09

-0.73

-1.03%

盘前70.72

+0.63+0.90%

08:02 EST

最高71.00	最低68.01	成交量155.54万
今开70.82	昨收70.82	日振幅4.22%
总市值95.24亿	流通市值83.35亿	总股本1.36亿
成交额1.08亿	换手率1.31%	流通股本1.19亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ARWR","market":"US","secType":"STK","nameCN":"Arrowhead Research Corporation","latestPrice":70.09,"timestamp":1765573200000,"preClose":70.82,"halted":0,"volume":1555372,"hourTrading":{"tag":"盘前","latestPrice":70.72,"preClose":70.09,"latestTime":"08:02 EST","volume":564,"amount":39767.783256,"timestamp":1765803729017},"delay":0,"floatShares":118912525,"shares":135879657,"eps":-0.012193,"marketStatus":"盘前交易","change":-0.73,"latestTime":"12-15 08:02:54 EST","open":70.82,"high":71,"low":68.01,"amount":108420720.40072002,"amplitude":0.04222,"askPrice":71.4,"askSize":350,"bidPrice":70.39,"bidSize":13,"shortable":3,"etf":0,"ttmEps":-0.012193,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765809000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":740203200000,"exchange":"NASDAQ","adjPreClose":70.09,"preHourTrading":{"tag":"盘前","latestPrice":70.72,"preClose":70.09,"latestTime":"08:02 EST","volume":564,"amount":39767.783256,"timestamp":1765803729017},"postHourTrading":{"tag":"盘后","latestPrice":69.7001,"preClose":70.09,"latestTime":"19:51 EST","volume":25518,"amount":1786482.5403,"timestamp":1765587100220},"volumeRatio":0.3617677889768921,"impliedVol":0.6445,"impliedVolPercentile":0.6225},"requestUrl":"/m/hq/s/ARWR/wiki","defaultTab":"wiki","newsList":[{"id":"1111227253","title":"Arrowhead Pharmaceuticals启动Aro-Mapt治疗阿尔茨海默病及其他tau病的1/2a期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1111227253","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111227253?lang=zh_cn&edition=full","pubTime":"2025-12-08 20:31","pubTimestamp":1765197073,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals启动Aro-Mapt治疗阿尔茨海默病及其他tau病的1/2a期研究","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARWR","BK4585","BK4588"],"gpt_icon":0},{"id":"1108529390","title":"Arrowhead Pharmaceuticals：计划在2026年底之前向FDA提交补充新药申请(SNDA)","url":"https://stock-news.laohu8.com/highlight/detail?id=1108529390","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1108529390?lang=zh_cn&edition=full","pubTime":"2025-12-02 20:31","pubTimestamp":1764678684,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals：计划在2026年底之前向FDA提交补充新药申请(SNDA)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4585","BK4139","ARWR"],"gpt_icon":0},{"id":"1151824926","title":"异动解读 | 分析师看好新药Redemplo及肥胖症资产数据，Arrowhead Research盘中大涨26.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=1151824926","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151824926?lang=zh_cn&edition=full","pubTime":"2025-11-27 04:30","pubTimestamp":1764189022,"startTime":"0","endTime":"0","summary":"Arrowhead Research Corporation（ARWR）今日盘中大涨26.10%，成为纳斯达克生物技术指数中的领涨股之一。消息面上，TD Cowen分析师在报告中指出，ARWR虽然报告了2025财年的亏损，但公司势头强劲，其新药Redemplo（用于治疗家族性乳糜微粒血症综合征）已成功上市。此外，分析师还提到，公司关于肥胖症资产的初步数据将于明年1月初公布，进一步提振了市场信心。生物技术板块近期表现强劲，纳斯达克生物技术指数本季度已上涨约19%，ARWR的突出表现也反映了市场对其创新管线的乐观预期。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ARWR"],"gpt_icon":0},{"id":"1129317410","title":"Arrowhead Pharmaceuticals宣布FDA批准Redemplo®（Plozasiran）用于降低家族性乳糜微粒血症（FCS）成人的甘油三酯","url":"https://stock-news.laohu8.com/highlight/detail?id=1129317410","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1129317410?lang=zh_cn&edition=full","pubTime":"2025-11-19 00:52","pubTimestamp":1763484733,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals宣布FDA批准Redemplo®（Plozasiran）用于降低家族性乳糜微粒血症（FCS）成人的甘油三酯。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"1121748631","title":"FDA批准Redemplo用于降低家族性乳糜微粒血症患者的甘油三酯","url":"https://stock-news.laohu8.com/highlight/detail?id=1121748631","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121748631?lang=zh_cn&edition=full","pubTime":"2025-11-19 00:17","pubTimestamp":1763482634,"startTime":"0","endTime":"0","summary":"FDA批准Redemplo用于降低家族性乳糜微粒血症患者的甘油三酯。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"1172633525","title":"Arrowhead Pharmaceuticals公布根据纳斯达克上市规则5635(C)(4)的激励授予","url":"https://stock-news.laohu8.com/highlight/detail?id=1172633525","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172633525?lang=zh_cn&edition=full","pubTime":"2025-10-29 05:55","pubTimestamp":1761688542,"startTime":"0","endTime":"0","summary":"10月28日 - Arrowhead Pharmaceuticals Inc：*ARROWHEAD PHARMACEUTICALS公布根据纳斯达克上市规则5635(C)(4)的激励授予","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARWR","BK4585","BK4588"],"gpt_icon":0},{"id":"1150998459","title":"Arrowhead Pharmaceuticals宣布与诺华签署全球许可及合作协议的完成","url":"https://stock-news.laohu8.com/highlight/detail?id=1150998459","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150998459?lang=zh_cn&edition=full","pubTime":"2025-10-21 19:30","pubTimestamp":1761046214,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals宣布与诺华签署全球许可及合作协议的完成","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR","BK4585","BK4588","BK4139"],"gpt_icon":0},{"id":"1145681364","title":"Arrowhead Pharmaceuticals为研究性药物ARO-DIMER-PA提交临床试验申请——首个治疗混合性高脂血症的双功能RNAi疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1145681364","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145681364?lang=zh_cn&edition=full","pubTime":"2025-10-07 19:33","pubTimestamp":1759836798,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals为研究性药物ARO-DIMER-PA提交临床试验申请——首个治疗混合性高脂血症的双功能RNAi疗法","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR","BK4139","BK4588","BK4585"],"gpt_icon":0},{"id":"2567327175","title":"Arrowhead Pharmaceuticals, Inc.盘中异动 下午盘股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2567327175","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567327175?lang=zh_cn&edition=full","pubTime":"2025-09-16 02:26","pubTimestamp":1757960795,"startTime":"0","endTime":"0","summary":"北京时间2025年09月16日02时26分，Arrowhead Pharmaceuticals, Inc.股票出现波动，股价快速跳水5.01%。Arrowhead Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.14%。其相关个股中，Metavia Inc.、Revolution Medicines Inc C/Wts 17/12/2026 、Protagenic Therapeutics Inc C/Wts 26/04/2026 涨幅较大，Salarius Pharmaceuticals, Inc.、Metavia Inc.、Atyr Pharma, Inc.较为活跃，换手率分别为577.39%、168.44%、133.08%，振幅较大的相关个股有Metavia Inc.、Revolution Medicines Inc C/Wts 17/12/2026 、Protagenic Therapeutics Inc C/Wts 26/04/2026 ，振幅分别为108.95%、66.63%、61.75%。Arrowhead Pharmaceuticals, Inc.公司简介：Arrowhead Pharmaceuticals Inc是一家美国生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250916022635a722ad64&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250916022635a722ad64&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4588","BK4585","ARWR"],"gpt_icon":0},{"id":"1112209112","title":"Arrowhead Pharmaceuticals申请监管许可，启动Aro-Mapt治疗阿尔茨海默病及其他tau蛋白病的1/2a期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1112209112","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112209112?lang=zh_cn&edition=full","pubTime":"2025-09-10 19:31","pubTimestamp":1757503870,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals已向监管机构申请许可，计划启动其药物Aro-Mapt用于治疗阿尔茨海默病及其他tau蛋白病的1/2a期临床研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4139","ARWR"],"gpt_icon":0},{"id":"2564319406","title":"Arrowhead Pharmaceuticals, Inc.盘中异动 股价大涨5.14%报27.00美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2564319406","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564319406?lang=zh_cn&edition=full","pubTime":"2025-09-03 21:39","pubTimestamp":1756906783,"startTime":"0","endTime":"0","summary":"北京时间2025年09月03日21时39分，Arrowhead Pharmaceuticals, Inc.股票出现波动，股价急速上涨5.14%。截至发稿，该股报27.00美元/股，成交量22.6617万股，换手率0.16%，振幅5.14%。Arrowhead Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.59%。其相关个股中，Osr Holdings Inc C/Wts 09/02/2028 、Shattuck Labs, Inc.、Relmada Therapeutics, Inc.涨幅较大，Promis Neurosciences Inc.、Novabay Pharmaceuticals, Inc.、Artelo Biosciences, Inc.较为活跃，换手率分别为77.25%、36.66%、20.84%，振幅较大的相关个股有Relmada Therapeutics, Inc.、Shattuck Labs, Inc.、Artelo Biosciences, Inc.，振幅分别为18.31%、17.82%、16.35%。Arrowhead Pharmaceuticals, Inc.公司简介：Arrowhead Pharmaceuticals Inc是一家美国生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250903213943a4b1f04e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250903213943a4b1f04e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4139","BK4585","ARWR"],"gpt_icon":0},{"id":"1158531109","title":"Arrowhead Pharmaceuticals盘前股价上涨1.2%，此前公司与Novartis就神经肌肉疗法许可达成20亿美元协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1158531109","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158531109?lang=zh_cn&edition=full","pubTime":"2025-09-02 20:31","pubTimestamp":1756816279,"startTime":"0","endTime":"0","summary":"Arrowhead Pharmaceuticals股价在盘前交易中上涨1.2%，此前该公司与Novartis签署了一项价值20亿美元的神经肌肉疗法许可协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ARWR","BK4588","BK4585"],"gpt_icon":0},{"id":"1128145583","title":"异动解读 | 业绩不及预期，Arrowhead Research Corporation股价盘中大跌5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=1128145583","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128145583?lang=zh_cn&edition=full","pubTime":"2025-08-08 21:56","pubTimestamp":1754661406,"startTime":"0","endTime":"0","summary":"生物制药公司Arrowhead Research Corporation今日盘中大跌5.21%，引发投资者关注。这一显著跌幅主要源于公司最新公布的季度财报未能达到市场预期。根据Arrowhead Pharmaceuticals Inc发布的财报显示，截至6月30日的季度调整后每股亏损为1.26美元，虽然相比去年同期的每股亏损1.38美元有所改善，但仍高于分析师平均预期的每股亏损1.03美元。尽管短期内股价承压，但分析师对Arrowhead Pharmaceuticals Inc的长期前景仍持乐观态度。华尔街给予Arrowhead Pharmaceuticals Inc的12个月目标价中位数为39.50美元，较其最新收盘价16.06美元高出约59.3%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ARWR"],"gpt_icon":0},{"id":"2557527259","title":"Arrowhead Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.04%报15.25美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2557527259","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2557527259?lang=zh_cn&edition=full","pubTime":"2025-08-08 21:36","pubTimestamp":1754660218,"startTime":"0","endTime":"0","summary":"北京时间2025年08月08日21时36分，Arrowhead Pharmaceuticals, Inc.股票出现波动，股价快速跳水5.04%。截至发稿，该股报15.25美元/股，成交量12.6659万股，换手率0.09%，振幅3.42%。Arrowhead Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.10%。其相关个股中，180 Life Sciences Corp C/Wts 07/11/2025、Bioxcel Therapeutics, Inc.、Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 涨幅较大，Onconetix, Inc.、Biovie Inc.、Bioxcel Therapeutics, Inc.较为活跃，换手率分别为88.31%、87.34%、76.22%，振幅较大的相关个股有180 Life Sciences Corp C/Wts 07/11/2025、Cognition Therapeutics, Inc.、Bioxcel Therapeutics, Inc.，振幅分别为35.00%、26.50%、18.16%。Arrowhead Pharmaceuticals, Inc.公司简介：Arrowhead Pharmaceuticals Inc是一家美国生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808213658a47d5d42&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250808213658a47d5d42&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","BK4585","BK4139","ARWR"],"gpt_icon":0},{"id":"1188417051","title":"Arrowhead 2025财年Q3业绩会总结及问答精华：临床进展与市场准备推动增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1188417051","media":"业绩会速递","labels":["earningsCall"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188417051?lang=zh_cn&edition=full","pubTime":"2025-08-08 06:33","pubTimestamp":1754605994,"startTime":"0","endTime":"0","summary":"管理层对Sarepta履行财务和商业义务充满信心，并认为这将为Arrowhead提供资金支持。预计Q4将确认1亿美元的里程碑付款。问题5：Sarepta持有Arrowhead股票的计划是什么？回答：现金将进入Vicerna，部分将分配给股东，Arrowhead持有56%的股份。Arrowhead Pharmaceuticals在临床试验和市场准备方面取得了显著进展，特别是在心血管和肥胖领域的RNAi技术应用。公司与Sarepta的合作为其提供了重要的资金支持，预计未来将有多个项目进入市场。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"earningsCall","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARWR"],"gpt_icon":0},{"id":"2551194869","title":"Arrowhead Pharmaceuticals, Inc.盘中异动 下午盘大幅下跌5.00%报17.68美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551194869","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551194869?lang=zh_cn&edition=full","pubTime":"2025-07-16 02:55","pubTimestamp":1752605757,"startTime":"0","endTime":"0","summary":"北京时间2025年07月16日02时55分，Arrowhead Pharmaceuticals, Inc.股票出现异动，股价快速下跌5.00%。截至发稿，该股报17.68美元/股，成交量63.4955万股，换手率0.46%，振幅6.50%。Arrowhead Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为1.24%。其相关个股中，Cyclacel Pharmaceuticals, Inc.、Kairos Pharma, Ltd.、Polyrizon Ltd.涨幅较大，Cyclacel Pharmaceuticals, Inc.、Polyrizon Ltd.、60 Degrees Pharmaceuticals, Inc.较为活跃，换手率分别为3520.75%、2114.80%、1562.50%，振幅较大的相关个股有Cyclacel Pharmaceuticals, Inc.、Kairos Pharma, Ltd.、Polyrizon Ltd.，振幅分别为444.11%、116.77%、75.50%。Arrowhead Pharmaceuticals, Inc.公司简介：Arrowhead Pharmaceuticals Inc是一家美国生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716025557a44cef2d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716025557a44cef2d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ARWR","BK4588","BK4585"],"gpt_icon":0},{"id":"2550823527","title":"Arrowhead Pharmaceuticals, Inc.盘中异动 快速拉升5.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2550823527","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550823527?lang=zh_cn&edition=full","pubTime":"2025-07-09 01:49","pubTimestamp":1751996955,"startTime":"0","endTime":"0","summary":"北京时间2025年07月09日01时49分，Arrowhead Pharmaceuticals, Inc.股票出现异动，股价大幅上涨5.11%。Arrowhead Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为1.08%。其相关个股中，Lakeshore Biopharma Co Ltd C/Wts 15/03/2028 、Zyversa Therapeutics, Inc.、Seastar Medical Holding Corporation涨幅较大，Zyversa Therapeutics, Inc.、Moleculin Biotech, Inc.、Rallybio Corporation较为活跃，换手率分别为4001.70%、620.69%、341.39%，振幅较大的相关个股有Zyversa Therapeutics, Inc.、Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 、Cero Therapeutics Holdings Inc C/Wts 13/02/2029 ，振幅分别为146.75%、73.81%、70.97%。Arrowhead Pharmaceuticals, Inc.公司简介：Arrowhead Pharmaceuticals Inc是一家美国生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709014916a43e82f0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709014916a43e82f0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ARWR","BK4588","BK4585","BK4139"],"gpt_icon":0},{"id":"2548814114","title":"Arrowhead Pharmaceuticals, Inc.盘中异动 下午盘股价大涨5.07%报16.91美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548814114","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548814114?lang=zh_cn&edition=full","pubTime":"2025-07-03 01:54","pubTimestamp":1751478892,"startTime":"0","endTime":"0","summary":"北京时间2025年07月03日01时54分，Arrowhead Pharmaceuticals, Inc.股票出现波动，股价大幅拉升5.07%。Arrowhead Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.89%。其相关个股中，Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 、Nutriband Inc C/Wts 、Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025涨幅较大，Sonnet Biotherapeutics Holdings, Inc.、Windtree Therapeutics, Inc.、Lixte Biotechnology Holdings, Inc.较为活跃，换手率分别为2515.91%、2036.48%、1250.78%，振幅较大的相关个股有Lixte Biotechnology Holdings  Inc C/Wts 30/11/2025 、Reviva Pharmaceuticals Holdings Inc C/Wts 25/12/2025、Sonnet Biotherapeutics Holdings, Inc.，振幅分别为1145.92%、393.59%、152.07%。Arrowhead Pharmaceuticals, Inc.公司简介：Arrowhead Pharmaceuticals Inc是一家美国生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070301545297978f8d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070301545297978f8d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ARWR","BK4139","BK4588","BK4585"],"gpt_icon":0},{"id":"2516727646","title":"Arrowhead Pharmaceuticals, Inc.盘中异动 急速跳水5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516727646","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516727646?lang=zh_cn&edition=full","pubTime":"2025-03-04 22:37","pubTimestamp":1741099028,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日22时37分，Arrowhead Pharmaceuticals, Inc.股票出现波动，股价大幅下挫5.14%。Arrowhead Pharmaceuticals, Inc.股票所在的生物技术行业中，整体跌幅为0.09%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Protagenic Therapeutics, Inc.、Capricor Therapeutics, Inc.涨幅较大，Aeon Biopharma, Inc.、Windtree Therapeutics, Inc.、Protagenic Therapeutics, Inc.较为活跃，换手率分别为1088.65%、1075.19%、426.90%，振幅较大的相关个股有Celularity Inc C/Wts 16/07/2026 、Hepion Pharmaceuticals, Inc.、Adma Biologics Inc，振幅分别为23.30%、22.25%、12.57%。Arrowhead Pharmaceuticals, Inc.公司简介：Arrowhead Pharmaceuticals Inc是一家美国生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223709abe7f1a9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304223709abe7f1a9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ARWR","BK4585","BK4588"],"gpt_icon":0},{"id":"2513472704","title":"Arrowhead Pharmaceuticals, Inc.盘中异动 早盘股价大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513472704","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513472704?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:02","pubTimestamp":1740409374,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时02分，Arrowhead Pharmaceuticals, Inc.股票出现波动，股价大幅下跌5.08%。截至发稿，该股报18.89美元/股，成交量10.6991万股，换手率0.08%，振幅4.92%。Arrowhead Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.24%。其相关个股中，Pepgen Inc.、Estrella Immunopharma Inc C/Wts 29/09/2028、Avalo Therapeutics, Inc.涨幅较大，Pepgen Inc.、Aditxt, Inc.、Biodexa Pharmaceuticals Plc较为活跃，换手率分别为156.52%、69.90%、25.47%，振幅较大的相关个股有Pepgen Inc.、Telix Pharmaceutic、Aspire Biopharma Holdings Inc C/Wts 14/02/2030 ，振幅分别为137.23%、55.69%、41.14%。Arrowhead Pharmaceuticals, Inc.公司简介：Arrowhead Pharmaceuticals Inc是一家美国生物技术公司。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230254a2521c2f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224230254a2521c2f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ARWR","BK4585","BK4588"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.arrowheadpharma.com","stockEarnings":[{"period":"1week","weight":0.1408},{"period":"1month","weight":0.6922},{"period":"3month","weight":1.3583},{"period":"6month","weight":3.453},{"period":"1year","weight":2.1658},{"period":"ytd","weight":2.7282}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Arrowhead Pharmaceuticals, Inc.最初于1989年在南达科他州注册成立，后在特拉华州重新注册成立。该公司开发药物，通过沉默疾病的基因来治疗疑难杂症。使用广泛的RNA化学组合和高效的递送模式，该公司的疗法触发RNA干扰机制，以诱导目标基因的快速、深度和持久敲低。目前有18个Arrowhead发现的候选药物处于早期（1期）至晚期（3期）的临床试验阶段。","yearOnYearQuotes":[{"month":1,"riseRate":0.47619,"avgChangeRate":0.008191},{"month":2,"riseRate":0.47619,"avgChangeRate":-0.00488},{"month":3,"riseRate":0.52381,"avgChangeRate":0.053201},{"month":4,"riseRate":0.47619,"avgChangeRate":0.025874},{"month":5,"riseRate":0.380952,"avgChangeRate":0.008317},{"month":6,"riseRate":0.571429,"avgChangeRate":0.023453},{"month":7,"riseRate":0.571429,"avgChangeRate":0.054423},{"month":8,"riseRate":0.428571,"avgChangeRate":0.013202},{"month":9,"riseRate":0.52381,"avgChangeRate":0.064131},{"month":10,"riseRate":0.454545,"avgChangeRate":-0.028468},{"month":11,"riseRate":0.545455,"avgChangeRate":0.060925},{"month":12,"riseRate":0.454545,"avgChangeRate":0.05809}],"exchange":"NASDAQ","name":"Arrowhead Research Corporation","nameEN":"Arrowhead Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Arrowhead Research Corporation(ARWR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Arrowhead Research Corporation(ARWR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Arrowhead Research Corporation,ARWR,Arrowhead Research Corporation股票,Arrowhead Research Corporation股票老虎,Arrowhead Research Corporation股票老虎国际,Arrowhead Research Corporation行情,Arrowhead Research Corporation股票行情,Arrowhead Research Corporation股价,Arrowhead Research Corporation股市,Arrowhead Research Corporation股票价格,Arrowhead Research Corporation股票交易,Arrowhead Research Corporation股票购买,Arrowhead Research Corporation股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Arrowhead Research Corporation(ARWR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Arrowhead Research Corporation(ARWR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}